MX2016005050A - Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenarativos. - Google Patents
Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenarativos.Info
- Publication number
- MX2016005050A MX2016005050A MX2016005050A MX2016005050A MX2016005050A MX 2016005050 A MX2016005050 A MX 2016005050A MX 2016005050 A MX2016005050 A MX 2016005050A MX 2016005050 A MX2016005050 A MX 2016005050A MX 2016005050 A MX2016005050 A MX 2016005050A
- Authority
- MX
- Mexico
- Prior art keywords
- semaphorin
- binding molecules
- neurodegenerative disorders
- treating neurodegenerative
- plexin
- Prior art date
Links
- 108010056102 CD100 antigen Proteins 0.000 title abstract 4
- 102100027744 Semaphorin-4D Human genes 0.000 title abstract 4
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 102100034384 Plexin-B1 Human genes 0.000 abstract 1
- 101710100559 Plexin-B1 Proteins 0.000 abstract 1
- 102100034383 Plexin-B2 Human genes 0.000 abstract 1
- 101710100551 Plexin-B2 Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporcionan en la presente métodos para aliviar los síntomas en un sujeto que tiene un trastorno neurodegenerativo, que comprenden la administración al sujeto una cantidad efectiva de una molécula de unión aislada que específicamente se une a Semaforina-4D (SEMA4D) o a sus receptores de Plexina-B1 o Plexina-B2. Además, se proporciona una molécula de unión aislada que se une específicamente al mismo epítopo SEMA4D como un anticuerpo de referencia seleccionado del grupo que consiste de VX1572503 y 67.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361893814P | 2013-10-21 | 2013-10-21 | |
US201461979384P | 2014-04-14 | 2014-04-14 | |
US201462012805P | 2014-06-16 | 2014-06-16 | |
PCT/US2014/061592 WO2015061330A1 (en) | 2013-10-21 | 2014-10-21 | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016005050A true MX2016005050A (es) | 2016-08-17 |
Family
ID=52826380
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016005050A MX2016005050A (es) | 2013-10-21 | 2014-10-21 | Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenarativos. |
MX2020009260A MX2020009260A (es) | 2013-10-21 | 2016-04-19 | Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenerativos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020009260A MX2020009260A (es) | 2013-10-21 | 2016-04-19 | Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenerativos. |
Country Status (19)
Country | Link |
---|---|
US (4) | US9598495B2 (es) |
EP (2) | EP3060252B1 (es) |
JP (2) | JP6461944B2 (es) |
KR (4) | KR20210118246A (es) |
CN (2) | CN106029093B (es) |
AU (3) | AU2014340210B2 (es) |
BR (1) | BR112016009047B1 (es) |
CA (2) | CA2927841C (es) |
DK (1) | DK3060252T3 (es) |
EA (1) | EA033072B1 (es) |
ES (1) | ES2773961T3 (es) |
IL (3) | IL275720B (es) |
MX (2) | MX2016005050A (es) |
NZ (1) | NZ630892A (es) |
PL (1) | PL3060252T3 (es) |
PT (1) | PT3060252T (es) |
SG (2) | SG10201707786QA (es) |
WO (1) | WO2015061330A1 (es) |
ZA (1) | ZA201602686B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA025245B1 (ru) | 2009-05-08 | 2016-12-30 | Вэксинекс, Инк. | Антитела против cd100 и способы их применения |
ES2669209T3 (es) | 2011-10-11 | 2018-05-24 | Vaccinex, Inc. | Uso de moléculas de unión a semaforina-4D para la modulación de la permeabilidad de la barrera hematoencefálica |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
WO2014116982A2 (en) * | 2013-01-25 | 2014-07-31 | Brandeis University | Methods of modulating gabaergic inhibitory synapse formation and function |
NZ631015A (en) | 2013-06-25 | 2019-08-30 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
PT3445397T (pt) | 2016-04-22 | 2023-01-13 | Vaccinex Inc | Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus |
AU2017306062B2 (en) | 2016-08-02 | 2021-12-09 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
JP7084689B2 (ja) * | 2016-12-08 | 2022-06-15 | 公益財団法人東京都医学総合研究所 | 脳組織の異常を伴う非ヒト動物の作製方法およびその利用 |
BR112019017367A2 (pt) * | 2017-02-22 | 2020-04-14 | Vaccinex Inc | detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias |
PT3600419T (pt) * | 2017-03-20 | 2023-11-16 | Vaccinex Inc | Tratamento do cancro com um anticorpo semaforina-4d em combinação com um agente modulador epigenético |
CN110636858B (zh) | 2017-05-05 | 2024-03-19 | 瓦西尼斯公司 | 人抗脑信号蛋白4d抗体 |
CN109410218B (zh) * | 2018-10-08 | 2020-08-11 | 百度在线网络技术(北京)有限公司 | 用于生成车辆损伤信息的方法和装置 |
EP3693380A1 (en) * | 2019-02-11 | 2020-08-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Dual inhibition of plexin-b1 and plexin-b2 |
MX2022016188A (es) * | 2020-06-25 | 2023-10-30 | Vaccinex Inc | Uso de moléculas de unión a semaforina-4d para el tratamiento del síndrome de rett. |
JPWO2022137964A1 (es) * | 2020-12-23 | 2022-06-30 | ||
AU2021465518A1 (en) * | 2021-09-27 | 2024-05-02 | Vaccinex, Inc. | Predictive outcome profiling for use of an anti-semaphorin-4d binding molecule to treat neurodegenerative disorders |
US20230331863A1 (en) | 2022-02-13 | 2023-10-19 | Vaccinex, Inc. | Combination therapy with semaphorin-4d blockade and htt-lowering agent for treatment of huntington's disease |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
US5070192A (en) | 1988-03-23 | 1991-12-03 | The Johns Hopkins University | Cloned human topoisomerase i: cdna expression, and use for autoantibody detection |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
US6497872B1 (en) | 1991-07-08 | 2002-12-24 | Neurospheres Holdings Ltd. | Neural transplantation using proliferated multipotent neural stem cells and their progeny |
FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
US5639856A (en) | 1993-09-13 | 1997-06-17 | The Regents Of The University Of California | Semaphorin gene family |
US5595756A (en) | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
US6576754B2 (en) | 1995-11-09 | 2003-06-10 | Dana-Farber Cancer Institute | CD100 antigen and uses therefor |
DE122007000021I1 (de) | 1997-04-07 | 2007-05-24 | Genentech Inc | Anti-vefg Antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
JP2001516226A (ja) | 1997-04-11 | 2001-09-25 | デンドレオン コーポレイション | 腫瘍関連性の抗原に対する免疫応答を誘導するための組成物および方法 |
EP0892047A3 (de) | 1997-07-09 | 2000-03-08 | Hoechst Marion Roussel Deutschland GmbH | Humanes und murines Semaphorin L |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
US6638501B1 (en) | 1997-09-29 | 2003-10-28 | Neurospheres Holdings Ltd. | Use of multipotent neural stem cell progeny to augment non-neural tissues |
US5958767A (en) | 1998-08-14 | 1999-09-28 | The Children's Medical Center Corp. | Engraftable human neural stem cells |
EP1137769B1 (en) | 1998-11-10 | 2008-09-03 | University Of Rochester | Methods for the generation of dna libraries |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
JP3787473B2 (ja) | 1999-11-30 | 2006-06-21 | 独立行政法人科学技術振興機構 | セマフォリン受容体 |
US6635742B1 (en) | 2000-01-25 | 2003-10-21 | Nuvelo, Inc. | Antibodies specific for semaphorin-like polypeptides |
AU2913801A (en) | 1999-12-23 | 2001-07-03 | Cornell Research Foundation Inc. | A method for isolating and purifying multipotential neural progenitor cells and multipotential neural progenitor cells |
JP2005500034A (ja) | 2001-06-20 | 2005-01-06 | プロション バイオテク リミテッド | 受容体型タンパク質チロシンキナーゼ活性化を遮断する抗体、そのスクリーニング方法、及びその使用 |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
EP1365018A1 (en) | 2002-05-23 | 2003-11-26 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | CD100 semaphorin in myelination |
BR0311471A (pt) | 2002-05-30 | 2007-04-27 | Macrogenics Inc | anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero |
EP1442749A1 (en) | 2003-01-31 | 2004-08-04 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system |
MXPA05012723A (es) | 2003-05-30 | 2006-02-08 | Genentech Inc | Tratamiento con anticuerpos anti-vgf. |
KR101195291B1 (ko) | 2003-12-11 | 2012-10-26 | 제넨테크, 인크. | C-met 이량체화 및 활성화를 억제하는 방법 및조성물 |
DE602005020799D1 (de) | 2004-08-05 | 2010-06-02 | Genentech Inc | Humanisierte anti-cmet-antagonisten |
US20060147449A1 (en) | 2004-11-15 | 2006-07-06 | Brass Lawrence F | Method of using CD100 (or Sema4D) to mediate platelet activation and inflammatory responses |
CA2603780A1 (en) | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics, Inc. | Sema4d in cancer diagnosis, detection and treatment |
JP2007308465A (ja) | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | 炎症性疾患、自己免疫疾患又は骨吸収異常の治療方法 |
WO2008100995A1 (en) | 2007-02-14 | 2008-08-21 | Vaccinex, Inc. | Humanized anti-cd100 antibodies |
US20090181035A1 (en) | 2008-01-10 | 2009-07-16 | Genentech, Inc. | Plexind1 agonists and their use |
EA025245B1 (ru) | 2009-05-08 | 2016-12-30 | Вэксинекс, Инк. | Антитела против cd100 и способы их применения |
JP5797190B2 (ja) | 2009-05-15 | 2015-10-21 | アイ アール エックス セーラピューティクス, インコーポレイテッド | ワクチン免疫療法 |
CA2802376A1 (en) | 2010-06-14 | 2011-12-22 | Vaccinex, Inc. | Anti-vegf antibodies and uses thereof |
CN103945868B (zh) | 2011-05-13 | 2016-10-26 | 国立大学法人东京医科齿科大学 | 骨生成促进剂 |
ES2669209T3 (es) | 2011-10-11 | 2018-05-24 | Vaccinex, Inc. | Uso de moléculas de unión a semaforina-4D para la modulación de la permeabilidad de la barrera hematoencefálica |
US8790652B2 (en) | 2011-12-06 | 2014-07-29 | Vaccinex, Inc. | Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis |
US9090709B2 (en) | 2012-03-28 | 2015-07-28 | Vaccinex, Inc. | Anti-SEMA4D antibodies and epitopes |
US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
US10494440B2 (en) | 2012-05-11 | 2019-12-03 | Vaccinex, Inc. | Use of semaphorin-4D binding molecules to promote neurogenesis following stroke |
NZ631015A (en) | 2013-06-25 | 2019-08-30 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
NZ630881A (en) | 2013-10-10 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treatment of atherosclerosis |
NZ630892A (en) | 2013-10-21 | 2016-03-31 | Vaccinex Inc | Use of semaphorin-4d binding molecules for treating neurodegenerative disorders |
PT3445397T (pt) | 2016-04-22 | 2023-01-13 | Vaccinex Inc | Exibição de proteína integral de membrana sobre viriões envelopados extracelulares de poxvírus |
AU2017306062B2 (en) | 2016-08-02 | 2021-12-09 | Vaccinex, Inc. | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
BR112019017367A2 (pt) | 2017-02-22 | 2020-04-14 | Vaccinex Inc | detecção precoce de ativação de célula glial em doenças neurodegenerativas ou neuroinflamatórias |
-
2014
- 2014-09-11 NZ NZ630892A patent/NZ630892A/en unknown
- 2014-10-21 AU AU2014340210A patent/AU2014340210B2/en active Active
- 2014-10-21 EP EP14855074.2A patent/EP3060252B1/en active Active
- 2014-10-21 CN CN201480070232.2A patent/CN106029093B/zh active Active
- 2014-10-21 IL IL275720A patent/IL275720B/en unknown
- 2014-10-21 BR BR112016009047-0A patent/BR112016009047B1/pt active IP Right Grant
- 2014-10-21 CA CA2927841A patent/CA2927841C/en active Active
- 2014-10-21 WO PCT/US2014/061592 patent/WO2015061330A1/en active Application Filing
- 2014-10-21 PL PL14855074T patent/PL3060252T3/pl unknown
- 2014-10-21 EA EA201690813A patent/EA033072B1/ru unknown
- 2014-10-21 SG SG10201707786QA patent/SG10201707786QA/en unknown
- 2014-10-21 CN CN202310282388.8A patent/CN116966293A/zh active Pending
- 2014-10-21 CA CA3193983A patent/CA3193983A1/en active Pending
- 2014-10-21 KR KR1020217030075A patent/KR20210118246A/ko not_active Application Discontinuation
- 2014-10-21 KR KR1020227025504A patent/KR102602502B1/ko active IP Right Grant
- 2014-10-21 MX MX2016005050A patent/MX2016005050A/es active IP Right Grant
- 2014-10-21 KR KR1020167013445A patent/KR102308493B1/ko active IP Right Grant
- 2014-10-21 PT PT148550742T patent/PT3060252T/pt unknown
- 2014-10-21 US US14/519,965 patent/US9598495B2/en active Active
- 2014-10-21 ES ES14855074T patent/ES2773961T3/es active Active
- 2014-10-21 KR KR1020237038769A patent/KR20230159633A/ko active Search and Examination
- 2014-10-21 IL IL295045A patent/IL295045B2/en unknown
- 2014-10-21 EP EP19208515.7A patent/EP3639853A1/en active Pending
- 2014-10-21 SG SG11201603167YA patent/SG11201603167YA/en unknown
- 2014-10-21 DK DK14855074.2T patent/DK3060252T3/da active
- 2014-10-21 JP JP2016524999A patent/JP6461944B2/ja active Active
-
2015
- 2015-06-29 US US14/753,882 patent/US9249227B2/en active Active
-
2016
- 2016-04-13 IL IL245089A patent/IL245089B/en active IP Right Grant
- 2016-04-19 ZA ZA201602686A patent/ZA201602686B/en unknown
- 2016-04-19 MX MX2020009260A patent/MX2020009260A/es unknown
-
2017
- 2017-03-21 US US15/465,509 patent/US10385136B2/en active Active
-
2018
- 2018-12-26 JP JP2018241924A patent/JP6875363B2/ja active Active
-
2019
- 2019-07-02 US US16/460,593 patent/US10800853B2/en active Active
- 2019-10-28 AU AU2019257379A patent/AU2019257379B2/en active Active
-
2021
- 2021-04-06 AU AU2021202095A patent/AU2021202095B9/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020009260A (es) | Uso de moleculas de union a semaforina-4d para el tratamiento de trastornos neurodegenerativos. | |
MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
PH12017502222A1 (en) | Lag-3-binding molecules and methods of use thereof | |
AU2018256498A1 (en) | Antibodies to amyloid beta | |
PH12019500261B1 (en) | Methods for treating osteogenesis imperfecta | |
BR112018012929A2 (pt) | anticorpos anti-cd20/anti-cd3 biespecíficos para tratar leucemia linfoblástica aguda | |
EA201690728A1 (ru) | Применение молекул, связывающих семафорин-4d, для лечения атеросклероза | |
UA118083C2 (uk) | ВИДІЛЕНЕ МОНОКЛОНАЛЬНЕ АНТИТІЛО ПРОТИ МОЛЕКУЛИ ВІДШТОВХУВАЛЬНОГО НАПРЯМНОГО СИГНАЛУ (RGMa) ТА ЙОГО ЗАСТОСУВАННЯ В ЛІКУВАННІ РОЗЛАДУ, АСОЦІЙОВАНОГО З ДЕГЕНЕРАЦІЄЮ НЕЙРИТІВ | |
CL2011002831A1 (es) | Anticuerpo humanizado especifico de la forma protofibrilar del peptido a-beta; uso de dicho anticuerpo para tratar transtornos neurodegenerativos; composicion farmaceutica; celula que produce dichos anticuerpos; y procedimientos de preparacion de dicho anticuerpo. | |
MX2019015738A (es) | Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos. | |
SG10201902924RA (en) | Antibodies that bind ebola glycoprotein and uses thereof | |
MX2015011670A (es) | Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5. | |
MY195289A (en) | Anti IL-36R Antibodies | |
MX341076B (es) | Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados. | |
MX359794B (es) | Anticuerpos anti-hepcidina y usos de los mismos. | |
EA201490768A1 (ru) | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера | |
PH12014501338A1 (en) | Chimeric therapeutic anti-cd37 antibodie hh1 | |
BR112018072066A2 (pt) | moléculas de ligação específicas para fcgamariia e uso das mesmas | |
MX2015016054A (es) | Terapia de combinacion anti-quimiocina del ligando 2 del motif c-c y anti-lisil oxidasa-tipo 2 para el tratamiento de escleroderma. | |
MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
MX2015002465A (es) | Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1). | |
EA201991020A3 (ru) | Применение семафорин-4d-связывающих молекул для лечения нейродегенеративных нарушений | |
AR124605A2 (es) | Anticuerpos anti-il-36r | |
NZ768582A (en) | Antibodies and uses thereof to detect folate receptor 1 | |
WO2014144616A3 (en) | Anti-alpha v beta 5 antibodies and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |